| Name | Title | Contact Details |
|---|
Rogers Behavioral Health has the expertise and experience found in a stand-alone, not-for-profit behavioral health system. Our specialized programs are known for their effectiveness in treating children, teens and adults with OCD and anxiety disorders, depression and mood disorders, eating disorders, posttraumatic stress disorder and addiction. We use proven, evidence-based treatments coupled with strong patient and family education. At Rogers, we create an environment where our patients and their families know what tomorrow will bring. Life. Worth. Living.
SOAR Medical Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Redwood City, CA. To find more information about SOAR Medical Group, please visit www.soarmedical.com
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
The Strategies is a healthcare company that consists of four interconnected healthcare companies formed and brought to fruition by Ron Cram and Jamey Kleva. The company strives to meet and exceed the needs of their partners by identifying and closing g...
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.